CClinicalTrials.gg
Not yet recruitingNCT07293598ROTATEUpdated Dec 19, 2025

Investigation of the ROle of faT and inflAmmaTory Cells in mElanoma

An observational study in Melanoma (Skin Cancer), sponsored by The Christie NHS Foundation Trust. Not yet recruiting at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by The Christie NHS Foundation Trust · Observational

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
20
Sex
All
01

Study summary

This study is a retrospective, proof-of-concept sample study to investigate a novel histological finding within the primary melanoma tumour in a large population of melanoma patients to assess its prognostic significance.

This is a aims to validate the striking observation that a cross-talk between fat cells and leukocytes at the primary melanoma site promotes metastasis. In our unpublished pilot study, we have discovered an interesting finding whereby inflammatory cells extend from the tumour to and invading fat in the subcutaneous tissue and/or around the appendageal structures in the dermal skin in metastatic melanomas with distinct architectural changes within the fat. This finding was consistently present in metastatic and absent in non-metastatic melanomas. This new finding has both clinical and pathophysiological credence. Archival tissue blocks or human cell lines will be used in the first instance. As mitigation, experiments will be repeated with conditioned media obtained from co-culture of mixed primary immune cells obtained from peripheral blood mononuclear cell (PBMCs) and adipocytes induced from stem cells.

This study aims to:

  • Investigate if the crosstalk between fat cells and tumour-infiltrating inflammatory cells defines the aggressiveness of primary cutaneous melanomas.
  • Identify and perform biological spatial analysis of the inflammatory cells between the tumour and fat in the primary tumours.
  • Investigate the interactions of fat cells and/or inflammatory cells in mediating melanoma cellular plasticity.

The patients have not provided consent and will be justified in this application

02

Conditions studied

  • Melanoma (Skin Cancer)

Browse trials for

03

In context

Melanoma

3,006 studies on the registry are indexed under Melanoma; 520 are open to participants now.

This study's planned enrollment of 20 is below the median of 182 across 438 observational studies indexed under Melanoma.

Browse Melanoma studies →

Lead sponsor

The Christie NHS Foundation Trust is the lead sponsor of 99 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Sample analysis of melanoma only

Inclusion criteria

  1. Melanomas treated between 1st January 2006 and 31st December 2015 OR
  2. Patients treated at the Christie between 2014 and 2019.
  3. Review of histological slides for presence or absence of relevant histological features.

    For group 3 and group 4:

  4. Unique features of spitzoid melanomas

Exclusion criteria

Exclusion Criteria:

  • Inadequate slide quality
  • Unable to view the entire cross section of the skin with the primary tumour hence, unable to assess the invasion of inflammatory cells into fat
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
20 participants (estimated)
Patient registry
No

Interventions

  • OtherSample analysis only

    Sample analysis only

06

What researchers measure

Primary outcomes

  1. What is the predictive accuracy of inflammatory cell invasion into the subcutaneous fat layer in primary melanoma for determining the risk of metastasis and/or disease progression?

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07293598
Lead sponsor
The Christie NHS Foundation Trust
Collaborators
University of Manchester
Responsible party
Sponsor
First posted
Dec 19, 2025
Start date
Jan 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Dec 19, 2025

Study contacts

Richa Garva, Dr
Contact
removed_due_to_spam@email.com
01614469999

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion